The blinded, placebo-controlled, escalating-dose will enroll 100 healthy adults 18 to 49 years old, who will be grouped into four cohorts and randomised to receive either vaccine treatment or saline placebo in a 4:1 ratio.
The interim top-line data from the trial is expected to be available in the third quarter of 2011.
Novavax president and CEO Rahul Singhvi said that the launch of this trial is timely because there are no vaccines currently approved for RSV disease.